Cargando…

ET-1 Translational research platform for malignant brain tumors

Introduction: The standard therapy for malignant brain tumors includes surgery and combination therapy with radiation and chemotherapy, but to provide individualized treatment based on the biological and molecular genetic background of the tumor, integrate genetic information with various functional...

Descripción completa

Detalles Bibliográficos
Autores principales: Tateishi, Kensuke, Miyake, Yohei, Nakamura, Taishi, Sasame, Jo, Hayashi, Takahiro, Oshima, Akito, Honma, Hirokuni, Ikegaya, Naoki, Yamamoto, Tetsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648230/
http://dx.doi.org/10.1093/noajnl/vdab159.014
_version_ 1784610762488020992
author Tateishi, Kensuke
Miyake, Yohei
Nakamura, Taishi
Sasame, Jo
Hayashi, Takahiro
Oshima, Akito
Honma, Hirokuni
Ikegaya, Naoki
Yamamoto, Tetsuya
author_facet Tateishi, Kensuke
Miyake, Yohei
Nakamura, Taishi
Sasame, Jo
Hayashi, Takahiro
Oshima, Akito
Honma, Hirokuni
Ikegaya, Naoki
Yamamoto, Tetsuya
author_sort Tateishi, Kensuke
collection PubMed
description Introduction: The standard therapy for malignant brain tumors includes surgery and combination therapy with radiation and chemotherapy, but to provide individualized treatment based on the biological and molecular genetic background of the tumor, integrate genetic information with various functional data are required. In this study, we present an overview of our integrated approaches for translational research and clinical management. Methods: In glioma, pre-and intra-operative clinical information, including intraoperative genetic diagnosis, and intraoperative rapid immunohistochemistry is obtained, then a multidisciplinary treatment approach is started based on these integrated data. Specimens collected intraoperatively are cryopreserved for future analysis, and primary cultured cells are routinely collected. The cultured cells are transplanted into the brain of immunodeficient mice to establish patient-derived xenograft model (PDX). Genetic screening, such as IDH, TERT, BRAF, H3F3A mutation and MGMT methylation analysis are routinely assessed within a few days after surgery and used as information for integrated diagnosis. In case of PDX establishment or recurrence, we perform whole exon sequencing or comprehensive genomic assessment to identify genetic abnormalities. If genomic alterations for possible molecular targeted therapy are identified, we assess drug sensitivity test in vitro and in vivo, which are utilized for research to develop optimal molecular targeted therapy. The results, such as the therapeutic effects of molecular targeted drugs, are used for clinical applications. Results: Since the platform was established, we have treated a total of 286 patients, including 189 gliomas and 37 central nervous system lymphomas based on the integrated information. We are currently collecting clinical data to examine if this integrated approach could provide clinical benefit.Conclusion: The translational research system for malignant brain tumors plays an important role in the promotion of clinical and basic research.
format Online
Article
Text
id pubmed-8648230
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86482302021-12-07 ET-1 Translational research platform for malignant brain tumors Tateishi, Kensuke Miyake, Yohei Nakamura, Taishi Sasame, Jo Hayashi, Takahiro Oshima, Akito Honma, Hirokuni Ikegaya, Naoki Yamamoto, Tetsuya Neurooncol Adv Supplement Abstracts Introduction: The standard therapy for malignant brain tumors includes surgery and combination therapy with radiation and chemotherapy, but to provide individualized treatment based on the biological and molecular genetic background of the tumor, integrate genetic information with various functional data are required. In this study, we present an overview of our integrated approaches for translational research and clinical management. Methods: In glioma, pre-and intra-operative clinical information, including intraoperative genetic diagnosis, and intraoperative rapid immunohistochemistry is obtained, then a multidisciplinary treatment approach is started based on these integrated data. Specimens collected intraoperatively are cryopreserved for future analysis, and primary cultured cells are routinely collected. The cultured cells are transplanted into the brain of immunodeficient mice to establish patient-derived xenograft model (PDX). Genetic screening, such as IDH, TERT, BRAF, H3F3A mutation and MGMT methylation analysis are routinely assessed within a few days after surgery and used as information for integrated diagnosis. In case of PDX establishment or recurrence, we perform whole exon sequencing or comprehensive genomic assessment to identify genetic abnormalities. If genomic alterations for possible molecular targeted therapy are identified, we assess drug sensitivity test in vitro and in vivo, which are utilized for research to develop optimal molecular targeted therapy. The results, such as the therapeutic effects of molecular targeted drugs, are used for clinical applications. Results: Since the platform was established, we have treated a total of 286 patients, including 189 gliomas and 37 central nervous system lymphomas based on the integrated information. We are currently collecting clinical data to examine if this integrated approach could provide clinical benefit.Conclusion: The translational research system for malignant brain tumors plays an important role in the promotion of clinical and basic research. Oxford University Press 2021-12-06 /pmc/articles/PMC8648230/ http://dx.doi.org/10.1093/noajnl/vdab159.014 Text en © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Abstracts
Tateishi, Kensuke
Miyake, Yohei
Nakamura, Taishi
Sasame, Jo
Hayashi, Takahiro
Oshima, Akito
Honma, Hirokuni
Ikegaya, Naoki
Yamamoto, Tetsuya
ET-1 Translational research platform for malignant brain tumors
title ET-1 Translational research platform for malignant brain tumors
title_full ET-1 Translational research platform for malignant brain tumors
title_fullStr ET-1 Translational research platform for malignant brain tumors
title_full_unstemmed ET-1 Translational research platform for malignant brain tumors
title_short ET-1 Translational research platform for malignant brain tumors
title_sort et-1 translational research platform for malignant brain tumors
topic Supplement Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648230/
http://dx.doi.org/10.1093/noajnl/vdab159.014
work_keys_str_mv AT tateishikensuke et1translationalresearchplatformformalignantbraintumors
AT miyakeyohei et1translationalresearchplatformformalignantbraintumors
AT nakamurataishi et1translationalresearchplatformformalignantbraintumors
AT sasamejo et1translationalresearchplatformformalignantbraintumors
AT hayashitakahiro et1translationalresearchplatformformalignantbraintumors
AT oshimaakito et1translationalresearchplatformformalignantbraintumors
AT honmahirokuni et1translationalresearchplatformformalignantbraintumors
AT ikegayanaoki et1translationalresearchplatformformalignantbraintumors
AT yamamototetsuya et1translationalresearchplatformformalignantbraintumors